Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Proteomic and Lipidomic Profiling of Aqueous Humor Reveals Inflammatory Signatures in Retinitis Pigmentosa.

Biomedicines·2026
Same author

Astrocyte/monocyte activation and inflammation are associated with asymptomatic neurocognitive impairment in people with HIV on suppressive antiretroviral therapy.

AIDS (London, England)·2026
Same author

<i>Roseburia</i>-Associated Gut-Brain Axis Alterations in Relapsing-Remitting Multiple Sclerosis: Evidence from a Household-Matched Case-Control Study.

Nutrients·2026
Same author

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

ABCB1 polymorphisms are associated with clinical response to nabiximols in patients with multiple sclerosis-related spasticity.

Journal of cannabis research·2025
Same author

Large Language Models in Neurological Practice: Real-World Study.

Journal of medical Internet research·2025
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
03:07

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Mitoxantrone for multiple sclerosis.

Filippo Martinelli Boneschi1, Laura Vacchi, Marco Rovaris

  • 1Department of Neurology, INSPE - San Raffaele Scientific Institute, Milano, Italy. filippo.martinelli@hsr.it

The Cochrane Database of Systematic Reviews
|June 4, 2013
PubMed
Summary
This summary is machine-generated.

Mitoxantrone (MX) moderately reduces multiple sclerosis (MS) progression and relapses in the short term. However, potential long-term risks like cardiac dysfunction and leukemia warrant cautious use and consideration of alternatives.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
03:07

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Mitoxantrone (MX) is a moderately effective treatment for reducing disease activity in multiple sclerosis (MS).
  • This review updates previous findings on MX efficacy and safety in MS patients.

Purpose of the Study:

  • To assess the efficacy and safety of Mitoxantrone (MX) compared to a control group.
  • To evaluate MX in patients with relapsing-remitting (RRMS), progressive relapsing (PRMS), and secondary progressive (SPMS) multiple sclerosis.

Main Methods:

  • Searched Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register and reference lists.
  • Included randomized, double-blinded, controlled trials (RCTs) comparing MX versus placebo.
  • Extracted clinical, safety, and MRI data; assessed risk of bias; used fixed-effect model for analysis.

Main Results:

  • Three trials with 221 participants showed MX reduced disability progression at two years.
  • Significant reductions observed in annualized relapse rate and active MRI lesions.
  • Reported side effects included amenorrhea, nausea, alopecia; no major adverse events in this review.

Conclusions:

  • Mitoxantrone (MX) demonstrates significant short-term efficacy in reducing MS progression and relapses.
  • Long-term concerns include potential cardiac dysfunction and leukemia risk.
  • MX use should be limited to specific patient groups after careful risk-benefit assessment, considering alternative therapies.